Skip to main content
Fig. 1 | BMC Research Notes

Fig. 1

From: Three-month early change in prostate-specific antigen levels as a predictive marker for overall survival during hormonal therapy for metastatic hormone-sensitive prostate cancer

Fig. 1

a Comparison of Kaplan–Meier curves between the high-risk group that satisfied three independent factors (Gleason score ≥ 8, EOD ≥ 2, and 3-month %PSA level ≥ 1) and the other group. The high-risk group shows a significantly shorter time to CRPC than the other group (p = 0.0171). b The AUC of CRPC diagnosis for differentiating the high-risk group and the other group is 0.822. That provides a sensitivity of 0.877 and a false-positive rate of 0.520

Back to article page